Astellas Extends Deal With Regeneron For Antibody Technology Built Around Growing Oncology Portfolio
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas has acknowledged that it is a late-comer to the oncology space, but an extension of a non-exclusive license to Regeneron's VelocImmune technology, potentially through 2023, signals the Japanese company's continued effort to become a significant player in the monoclonal antibody space